NAMSA and APS: Providing Full Continuum MedTech Development Solutions

In March 2021, American Preclinical Services (APS) announced its acquisition by NAMSA, the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Founded in 1967, NAMSA is the pioneer of the medical device testing industry and has expanded over the years to offer full development lifecycle solutions to Sponsors worldwide. These services include laboratory and preclinical testing; quality, reimbursement and regulatory consulting; clinical research solutions; IVD services and more.

APS, now part of NAMSA, looks forward to continuing to offer Clients the most proven, trusted preclinical research solutions in the MedTech industry. APS Clients will also benefit from the breadth and depth of NAMSA’s full development service offerings, including:

NAMSA APEX PROGRAM: Full Development Lifecycle Resource
Biological Safety Consulting
EU MDR & IVDR Consulting Services
Quality and Regulatory Consulting
US FDA Consulting Services
Medical Device Testing
Medical Device and IVD Market Research

Stay Informed on the Latest Industry Updates: NAMSA is proud to offer Clients a full suite of complimentary resources, providing critical information gained throughout NAMSA’s 55+ year history of effectively managing innovative development programs for global Sponsors. Access these to learn best practices and proven strategies critical to successful market introduction and commercialization. To be informed of important industry updates, resources and events, we invite you to sign up for NAMSA’s Newsletter, below.